Drugs / DHEA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03648385 | Jan 2019 → Jun 2024 | pulmonary arterial hypertension | Rhode Island Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DHEA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03648385 ↗ |
| Modality | Small molecule | “The adrenal steroid dehydroepiandrosterone (DHEA) and its sulfated form (DHEA-S) are deficient in pulmonary arterial hypertension (PAH)” PMID 40766123 ↗ Aug 2025 |
| Route | Oral | “DHEA tablet (50 mg) taken by mouth once a day for 18 weeks” NCT03648385 ↗ |